French pharmaceutical company AB Science (Euronext Paris:AB) announced on Monday that the European Medicines Agency (EMA) has approved a shelf-life extension for its veterinary drug Masivet, increasing it from 36 to 48 months.
This approval applies specifically to the 50mg tablet formulation currently available in the European Union.
Masivet is indicated for the treatment of non-resectable Grade 2 or 3 mast cell tumours in dogs with confirmed c-kit tyrosine kinase receptor mutations. The product is marketed by AB Science and is accessible in all EU member states.
The extended shelf life enhances inventory flexibility for AB Science, veterinary caregivers and patients. It also reduces the risk of product expiration and supports uninterrupted access to treatment.
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid